TY - JOUR
TI - Increased myeloperoxidase plasma levels in patients with alzheimer's disease
AU - Tzikas, S.
AU - Schlak, D.
AU - Sopova, K.
AU - Gatsiou, A.
AU - Stakos, D.
AU - Stamatelopoulos, K.
AU - Stellos, K.
AU - Laske, C.
JO - Journal of Alzheimer's disease : JAD
PY - 2014
VL - 39
TODO - 3
SP - 557-564
PB - IOS Press BV
SN - null
TODO - 10.3233/JAD-131469
TODO - amyloid beta protein[1-40];  amyloid beta protein[1-42];  biological marker;  myeloperoxidase, aged;  Alzheimer disease;  article;  atherosclerosis;  blood level;  blood sampling;  clinical article;  controlled study;  diabetes mellitus;  disease association;  dyslipidemia;  enzyme immunoassay;  female;  human;  hypertension;  male;  neurologic disease;  priority journal;  risk factor;  smoking, Alzheimer's disease;  amyloid-β;  dementia;  myeloperoxidase, Aged;  Aged, 80 and over;  Alzheimer Disease;  Amyloid beta-Peptides;  Female;  Humans;  Immunoenzyme Techniques;  Logistic Models;  Male;  Mental Status Schedule;  Neuropsychological Tests;  Peptide Fragments;  Peroxidase;  ROC Curve
TODO - Background: Increasing evidence supports the role of cardiovascular risk factors in the development of Alzheimer's disease (AD). Objective: In the present pilot study, we investigated plasma concentrations of myeloperoxidase (MPO) and its possible association with plasma amyloid-β (Aβ) 1-42/1-40 ratio in AD patients and elderly healthy controls. Methods: The study sample included 28 AD patients and 27 elderly individuals with a normal cognitive status as a control group. The Mini-Mental Status Examination was used to determine the global cognition. MPO, Aβ1-40, and Aβ1-42 plasma concentrations were measured by enzyme linked immunoabsorbent assays. Results: AD patients showed significantly higher plasma concentrations of MPO in comparison to healthy elderly controls (AD versus healthy elderly controls (mean ± SD): 132.8 ± 114.8 ng/mL versus 55.0 ± 42.6 ng/mL; p = 0.002). MPO plasma concentrations showed a significant positive correlation in the whole sample with the presence of AD (ρ = 0.428, p < 0.001) and its stage (ρ = 0.331; p = 0.013) as well as with plasma concentrations of Aβ1-42 (ρ = 0.406; p = 0.004) and Aβ1-42/1-40 ratio (ρ = 0.354; p = 0.013). In a binary logistic regression model, plasma MPO concentrations were independently associated with the presence of AD (p = 0.014). Conclusion: AD patients showed significantly increased plasma levels of MPO, which could be an important molecular link between atherosclerosis and AD. Further studies should evaluate whether MPO may also be a useful biomarker and potential new treatment target in AD. © 2014-IOS Press and the authors. All rights reserved.
ER -